{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-255200","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.795973+00:00","generated_at":"2026-05-30T02:08:30.788262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update","bullets":["Completed successful end-of-Phase 2 meeting with FDA for bitopertin in EPP, reaching alignment on all proposed study parameters with potential for accelerated approval.","Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in NDD-CKD patients with anemia at ASN Kidney Week 2024.","Ended Q3 2024 with $487M cash; closed $200M non-dilutive debt financing with Hercules Capital in November 2024.","Net loss was $26.6M for Q3 2024, compared to $14.1M for same period in 2023.","Appointed Steve Caffé as Chief Regulatory Officer and Rahul Kaushik as Chief Technical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-255200","json":"https://secwatch.observer/filing/0001193125-24-255200.json","markdown":"https://secwatch.observer/filing/0001193125-24-255200.md","text":"https://secwatch.observer/filing/0001193125-24-255200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/0001193125-24-255200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:08:30.788262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}